2026 Q2 -tulosraportti
35 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
3,91%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 173 | DDB | DDB | ||
| 171 | - | - | ||
| 170 | - | - | ||
| 341 | - | - | ||
| 25 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·4 min sittenArguments for waiting (The cautious investor / Trader)Technical headwinds and sell signals: Looking at the stock's technical momentum, the picture is weak. Analysis houses like Investtech and platforms like TradeDesk have triggered short-term sell and hold signals. The price has broken important support levels, and technically, the stock risks falling further towards the next support level around 270 DKK. [1] (https://tradedesk.dk/stock/novo-b.co#:~:text=Novo%20Nordisk%20%28NOVO%2DB%29,selv%20om%20aktien%20passer)Price pressure in the USA: The American Trump administration has entered into price agreements on obesity medication for 2026, which pressures Novo's advances and margins. [1] (https://global.morningstar.com/en-nd/stocks/novo-nordisk-what-we-think-stock-after-earnings#:~:text=NOVO%20B%20saw%206%25,expands.)Increased competition: Competitor Eli Lilly is stirring with new clinical data for their pill and weekly treatments, and generic (copied) medicine has already been launched in countries like Brazil and Canada.
·2 t sittenInterest rates will rise.. US Treasury Secretary Scott Bessent has attempted several forms of financial power. In early August, Bessent quite remarkably helped Japan strengthen its currency by selling euros and instead buying yen. Japan is the largest investor in US government bonds, and Bessent wants to avoid Japan selling off its dollar debt, because that would increase US interest rates even more. Later, Bessent also announced that he will buy back long-term US government debt and instead issue new short-term debt under 1 year - so-called T-bills - where the interest rate is lower. A shortcut to reduce total interest expenses. But it makes the US federal budget more dependent on what central bank chief Warsh does, as it is the central bank's interest rate that determines the interest rate on T-bills. And that only increases the Trump administration's pressure on central bank chief Warsh for lower interest rates. Perhaps even the debt crisis everyone fears.
·2 t sitten · MuokattuWhen one looks at picture1, which was the last time we were at that level, there was a completely different trading activity than what we see these days in picture2! It's nothing but some "trifles" that are pushing the price down these days🙃😊 How seriously should one really take it??
Watch out, now there will be lying again. You can't just cherry-pick different days. Do you want to compare the average for the last quarter? Year? Choose a period.
3 t sitten$NVO is expanding peptide API capacity quite significantly. They are building 2 huge purification factories with 3 mega lines in each. At a price about $3B per factory. Each line can produce multiple tons per year. They also need that with current wegovy pill run rate already approaching 5 tons API per year Only 1 of the 6 lines is operational. Number 2 should kick in any day. At that specific site they have announced expansion for about $13B since late 2021. Most going towards peptide API. LLY ceo said earlier this year that LLY and NVO had about 80% of global peptide API capacity announced. Including all other BP and CDMOs https://x.com/researchpulse1/status/2097444100463108227?s=46
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Danske Bank A/S | 173 | 173 | 0 | 173 |
| Anonyymi | 4 429 800 | 4 429 800 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Danske Bank A/S | 173 | 173 | 0 | 173 |
| Anonyymi | 4 429 800 | 4 429 800 | 0 | 0 |
2026 Q2 -tulosraportti
35 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
3,91%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·4 min sittenArguments for waiting (The cautious investor / Trader)Technical headwinds and sell signals: Looking at the stock's technical momentum, the picture is weak. Analysis houses like Investtech and platforms like TradeDesk have triggered short-term sell and hold signals. The price has broken important support levels, and technically, the stock risks falling further towards the next support level around 270 DKK. [1] (https://tradedesk.dk/stock/novo-b.co#:~:text=Novo%20Nordisk%20%28NOVO%2DB%29,selv%20om%20aktien%20passer)Price pressure in the USA: The American Trump administration has entered into price agreements on obesity medication for 2026, which pressures Novo's advances and margins. [1] (https://global.morningstar.com/en-nd/stocks/novo-nordisk-what-we-think-stock-after-earnings#:~:text=NOVO%20B%20saw%206%25,expands.)Increased competition: Competitor Eli Lilly is stirring with new clinical data for their pill and weekly treatments, and generic (copied) medicine has already been launched in countries like Brazil and Canada.
- ·2 t sittenInterest rates will rise.. US Treasury Secretary Scott Bessent has attempted several forms of financial power. In early August, Bessent quite remarkably helped Japan strengthen its currency by selling euros and instead buying yen. Japan is the largest investor in US government bonds, and Bessent wants to avoid Japan selling off its dollar debt, because that would increase US interest rates even more. Later, Bessent also announced that he will buy back long-term US government debt and instead issue new short-term debt under 1 year - so-called T-bills - where the interest rate is lower. A shortcut to reduce total interest expenses. But it makes the US federal budget more dependent on what central bank chief Warsh does, as it is the central bank's interest rate that determines the interest rate on T-bills. And that only increases the Trump administration's pressure on central bank chief Warsh for lower interest rates. Perhaps even the debt crisis everyone fears.
- ·2 t sitten · MuokattuWhen one looks at picture1, which was the last time we were at that level, there was a completely different trading activity than what we see these days in picture2! It's nothing but some "trifles" that are pushing the price down these days🙃😊 How seriously should one really take it??Watch out, now there will be lying again. You can't just cherry-pick different days. Do you want to compare the average for the last quarter? Year? Choose a period.
- 3 t sitten$NVO is expanding peptide API capacity quite significantly. They are building 2 huge purification factories with 3 mega lines in each. At a price about $3B per factory. Each line can produce multiple tons per year. They also need that with current wegovy pill run rate already approaching 5 tons API per year Only 1 of the 6 lines is operational. Number 2 should kick in any day. At that specific site they have announced expansion for about $13B since late 2021. Most going towards peptide API. LLY ceo said earlier this year that LLY and NVO had about 80% of global peptide API capacity announced. Including all other BP and CDMOs https://x.com/researchpulse1/status/2097444100463108227?s=46
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 173 | DDB | DDB | ||
| 171 | - | - | ||
| 170 | - | - | ||
| 341 | - | - | ||
| 25 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Danske Bank A/S | 173 | 173 | 0 | 173 |
| Anonyymi | 4 429 800 | 4 429 800 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Danske Bank A/S | 173 | 173 | 0 | 173 |
| Anonyymi | 4 429 800 | 4 429 800 | 0 | 0 |
2026 Q2 -tulosraportti
35 päivää sitten
‧1 t 2 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
3,75 DKK/osake
Viimeisin osinko
3,91%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·4 min sittenArguments for waiting (The cautious investor / Trader)Technical headwinds and sell signals: Looking at the stock's technical momentum, the picture is weak. Analysis houses like Investtech and platforms like TradeDesk have triggered short-term sell and hold signals. The price has broken important support levels, and technically, the stock risks falling further towards the next support level around 270 DKK. [1] (https://tradedesk.dk/stock/novo-b.co#:~:text=Novo%20Nordisk%20%28NOVO%2DB%29,selv%20om%20aktien%20passer)Price pressure in the USA: The American Trump administration has entered into price agreements on obesity medication for 2026, which pressures Novo's advances and margins. [1] (https://global.morningstar.com/en-nd/stocks/novo-nordisk-what-we-think-stock-after-earnings#:~:text=NOVO%20B%20saw%206%25,expands.)Increased competition: Competitor Eli Lilly is stirring with new clinical data for their pill and weekly treatments, and generic (copied) medicine has already been launched in countries like Brazil and Canada.
- ·2 t sittenInterest rates will rise.. US Treasury Secretary Scott Bessent has attempted several forms of financial power. In early August, Bessent quite remarkably helped Japan strengthen its currency by selling euros and instead buying yen. Japan is the largest investor in US government bonds, and Bessent wants to avoid Japan selling off its dollar debt, because that would increase US interest rates even more. Later, Bessent also announced that he will buy back long-term US government debt and instead issue new short-term debt under 1 year - so-called T-bills - where the interest rate is lower. A shortcut to reduce total interest expenses. But it makes the US federal budget more dependent on what central bank chief Warsh does, as it is the central bank's interest rate that determines the interest rate on T-bills. And that only increases the Trump administration's pressure on central bank chief Warsh for lower interest rates. Perhaps even the debt crisis everyone fears.
- ·2 t sitten · MuokattuWhen one looks at picture1, which was the last time we were at that level, there was a completely different trading activity than what we see these days in picture2! It's nothing but some "trifles" that are pushing the price down these days🙃😊 How seriously should one really take it??Watch out, now there will be lying again. You can't just cherry-pick different days. Do you want to compare the average for the last quarter? Year? Choose a period.
- 3 t sitten$NVO is expanding peptide API capacity quite significantly. They are building 2 huge purification factories with 3 mega lines in each. At a price about $3B per factory. Each line can produce multiple tons per year. They also need that with current wegovy pill run rate already approaching 5 tons API per year Only 1 of the 6 lines is operational. Number 2 should kick in any day. At that specific site they have announced expansion for about $13B since late 2021. Most going towards peptide API. LLY ceo said earlier this year that LLY and NVO had about 80% of global peptide API capacity announced. Including all other BP and CDMOs https://x.com/researchpulse1/status/2097444100463108227?s=46
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 173 | DDB | DDB | ||
| 171 | - | - | ||
| 170 | - | - | ||
| 341 | - | - | ||
| 25 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Danske Bank A/S | 173 | 173 | 0 | 173 |
| Anonyymi | 4 429 800 | 4 429 800 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Danske Bank A/S | 173 | 173 | 0 | 173 |
| Anonyymi | 4 429 800 | 4 429 800 | 0 | 0 |